<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Eskandari SK</submitter><funding>American Heart Association</funding><funding>Qatar Foundation</funding><funding>NIAID NIH HHS</funding><funding>American Diabetes Association</funding><funding>National Institutes of Health</funding><pagination>899975</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9229986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13</volume><pubmed_abstract>Regulatory T cells (T&lt;sub>regs&lt;/sub>) have shown great promise as a means of cellular therapy in a multitude of allo- and auto-immune diseases-due in part to their immunosuppressive potency. Nevertheless, the clinical efficacy of human T&lt;sub>regs&lt;/sub> in patients has been limited by their poor &lt;i>in vivo&lt;/i> homeostasis. To avert apoptosis, T&lt;sub>regs&lt;/sub> require stable antigenic (CD3ζ/T-cell-receptor-mediated), co-stimulatory (CD28-driven), and cytokine (IL-2-dependent) signaling. Notably, this sequence of signals supports an activated T&lt;sub>reg&lt;/sub> phenotype that includes a high expression of granzymes, particularly granzyme B (GrB). Previously, we have shown that aside from the functional effects of GrB in lysing target cells to modulate allo-immunity, GrB can leak out of the intracellular lysosomal granules of host T&lt;sub>regs&lt;/sub>, initiating pro-apoptotic pathways. Here, we assessed the role of inhibiting mechanistic target of rapamycin complex 1 (mTORC1), a recently favored drug target in the transplant field, in regulating human T&lt;sub>reg&lt;/sub> apoptosis &lt;i>via&lt;/i> GrB. Using &lt;i>ex vivo&lt;/i> models of human T&lt;sub>reg&lt;/sub> culture and a humanized mouse model of human skin allotransplantation, we found that by inhibiting mTORC1 using rapamycin, intracytoplasmic expression and functionality of GrB diminished in host T&lt;sub>regs&lt;/sub>; lowering human T&lt;sub>reg&lt;/sub> apoptosis by in part decreasing the phosphorylation of S6K and c-Jun. These findings support the already clinically validated effects of mTORC1 inhibition in patients, most notably their stabilization of T&lt;sub>reg&lt;/sub> bioactivity and &lt;i>in vivo&lt;/i> homeostasis.</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis.</pubmed_title><pmcid>PMC9229986</pmcid><funding_grant_id>R01 AI134842</funding_grant_id><pubmed_authors>Pomahac B</pubmed_authors><pubmed_authors>Chu P</pubmed_authors><pubmed_authors>Kollar B</pubmed_authors><pubmed_authors>Deban C</pubmed_authors><pubmed_authors>Sulkaj I</pubmed_authors><pubmed_authors>Sanders JSF</pubmed_authors><pubmed_authors>Melhem G</pubmed_authors><pubmed_authors>Saad AJ</pubmed_authors><pubmed_authors>Allos H</pubmed_authors><pubmed_authors>Azzi JR</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Al Dulaijan BS</pubmed_authors><pubmed_authors>Berger SP</pubmed_authors><pubmed_authors>Eskandari SK</pubmed_authors><pubmed_authors>Riella LV</pubmed_authors><pubmed_authors>Alhaddad JB</pubmed_authors><pubmed_authors>Choi JY</pubmed_authors><pubmed_authors>Lieberman J</pubmed_authors></additional><is_claimable>false</is_claimable><name>mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis.</name><description>Regulatory T cells (T&lt;sub>regs&lt;/sub>) have shown great promise as a means of cellular therapy in a multitude of allo- and auto-immune diseases-due in part to their immunosuppressive potency. Nevertheless, the clinical efficacy of human T&lt;sub>regs&lt;/sub> in patients has been limited by their poor &lt;i>in vivo&lt;/i> homeostasis. To avert apoptosis, T&lt;sub>regs&lt;/sub> require stable antigenic (CD3ζ/T-cell-receptor-mediated), co-stimulatory (CD28-driven), and cytokine (IL-2-dependent) signaling. Notably, this sequence of signals supports an activated T&lt;sub>reg&lt;/sub> phenotype that includes a high expression of granzymes, particularly granzyme B (GrB). Previously, we have shown that aside from the functional effects of GrB in lysing target cells to modulate allo-immunity, GrB can leak out of the intracellular lysosomal granules of host T&lt;sub>regs&lt;/sub>, initiating pro-apoptotic pathways. Here, we assessed the role of inhibiting mechanistic target of rapamycin complex 1 (mTORC1), a recently favored drug target in the transplant field, in regulating human T&lt;sub>reg&lt;/sub> apoptosis &lt;i>via&lt;/i> GrB. Using &lt;i>ex vivo&lt;/i> models of human T&lt;sub>reg&lt;/sub> culture and a humanized mouse model of human skin allotransplantation, we found that by inhibiting mTORC1 using rapamycin, intracytoplasmic expression and functionality of GrB diminished in host T&lt;sub>regs&lt;/sub>; lowering human T&lt;sub>reg&lt;/sub> apoptosis by in part decreasing the phosphorylation of S6K and c-Jun. These findings support the already clinically validated effects of mTORC1 inhibition in patients, most notably their stabilization of T&lt;sub>reg&lt;/sub> bioactivity and &lt;i>in vivo&lt;/i> homeostasis.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T19:13:23.343Z</modification><creation>2025-04-04T19:13:23.343Z</creation></dates><accession>S-EPMC9229986</accession><cross_references><pubmed>35757726</pubmed><doi>10.3389/fimmu.2022.899975</doi></cross_references></HashMap>